The Federal Biomedical Agency (FMBA RF) has begun clinical trials of its coronavirus vaccine. The developer was the St. Petersburg Research Institute of Vaccines and Serums FMBA.
As reported on July 19 in the press service of the agency, the new drug is mainly aimed at the development of cellular immunity. Clinical trials of phases I and II of the subunit recombinant vaccine begin with the official permission of the Ministry of Health of the Russian Federation today.
It is also known that 200 research participants between the ages of 18 and 60 will help scientists work on a vaccine. A month earlier, specialists successfully completed preclinical trials, making sure of the safety, efficacy and protective potential of the vaccine.
Recall that in April this year, employees of the Smorodintsev Research Institute of Influenza began the development of another vaccine against COVID-19. Her clinical trials are due to begin in the fall.